REG-Mydecine Innovations Group Inc: Doc re: Bl-Weekly Status Report

Mydecine InnovationsAnnouncement

14/06/2024 07:15

MYDECINE PROVIDES Bl-WEEKLY STATUS REPORT

Vancouver, British Columbia, June 14, 2024- Mydecine Innovations Group Inc.
(the "Company") (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) provides
this update on the status of a management cease trade order granted on May 2,
2024 (the "MCTO") by the British Columbia Securities Commission under National
Policy 12-203 - Management Cease Trade Order ("NP 12-203").

On May 3, 2024, the Company announced that, for reasons disclosed in the news
release, there would be a delay in the filing of its financial statements and
accompanying management's discussion and analysis for the fiscal year ended
December 31, 2023 (the "Annual Filings") beyond the period prescribed under
applicable Canadian securities laws (the "Default Announcement").

The Company reports that the audit is progressing and will provide a further
update on the timing of its Annual Filings on or about June 21, 2024. The
Company is also progressing on completion of its interim financial statement
and accompanying management's discussion and analysis for the first quarter
ended March 31, 2024, and will provide a further update on or about June 21,
2024. Further updates on timing will be provided by the Company as necessary.

During the MCTO, the general investing public will continue to be able to
trade in the Company's listed common shares. However, the Company's Chief
Executive Office and Chief Financial Officer will not be able to trade in the
Company's common shares.

Other than as disclosed in this news release, there are no material changes to
the information contained in the Default Announcement. The Company confirms
that it intends to satisfy the provisions of NP 12- 203 and will continue to
issue bi-weekly default status reports for so long as it remains in default of
the Annual Filings requirement.

The Company also announces that is has cancelled its Annual General and
Special Meeting (the "Meeting") scheduled for July 19, 2024. The Meeting will
be rescheduled in due course once a new meeting date has been determined.
Further updates on timing will be provided by the Company as necessary.

The Directors of Mydecine take responsibility for this announcement.

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.

On behalf of the Board of Directors,

MYDECINE INNOVATIONS GROUP INC.

Joshua Bartch

Chief Executive Officer

contact@mydecineinc.com

 

AQSE Corporate Advisor

Novum Securities Limited  Tel: +44 (0)207 399 9400

David Coffman/ George Duxberry

 

About Mydecine Innovations Group Inc.

Mydecine Innovations Group™ is a biotechnology company developing the next
generation of innovative medications and therapies to address mental health
disorders such as nicotine addiction and posttraumatic stress disorder (PTSD).
The core strategy blends advanced technology with an elaborate infrastructure
for drug discovery and development. Mydecine's dedicated multinational team
constantly develops new paths for breakthrough treatment solutions in areas
with considerable unmet needs. By collaborating with some of the world's
leading specialists, the Company aspires to responsibly speed up the
development of breakthrough medications to provide patients with safer and
more effective treatment solutions. At the same time, Mydecine's approach
focuses on the next generation of psychedelic medicine by creating innovative
compounds with unmatched therapeutic potential through its clinical trial
efforts with worldclass scientific and regulatory expertise.

Learn more at: https://www.mydecine.com/ and follow the company on Twitter,
LinkedIn, YouTube, and Instagram.

Forward-looking Information Statement

This news release may contain certain "forward-looking statements" and
"forward-looking information" within the meaning of applicable Canadian and
United States securities laws. When used in this news release, the words
"anticipate", "believe", "estimate", "expect", "target, "plan", "forecast",
"may", "schedule" and other similar words or expressions identify
forward-looking statements or information. These forward-looking statements or
information may relate to the anticipated timing for the filing of the Annual
Filings, and other factors or information. Such statements represent the
Company's current views with respect to future events and are necessarily
based upon a number of assumptions and estimates that, while considered
reasonable by the Company, are inherently subject to significant business,
economic, competitive, political and social risks, contingencies and
uncertainties. Many factors, both known and unknown, could cause results,
performance or achievements to be materially different from the results,
performance or achievements that are or may be expressed or implied by such
forward-looking statements. The Company does not intend, and does not assume
any obligation, to update these forward-looking statements or information to
reflect changes in assumptions or changes in circumstances or any other events
affections such statements and information other than as required by
applicable laws, rules and regulations

NEITHER THE CSE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT
RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.



Copyright (c) 2024 PR Newswire Association,LLC. All Rights Reserved